



Fatima Mechta-Grigoriou Chef d'équipe

EQUIPE MECHTA-GRIGORIOU

Directeur adjoint d'unité

Stress et cancer

fatima.mechta-grigoriou@curie.fr Tél : +33 (0)1 56 24 66 53



Publications clés

Année de publication : 2017

Gentric G, Mieulet V, Mechta-Grigoriou F (2017 Mar 20)

Heterogeneity in Cancer Metabolism: New Concepts in an Old Field.

Antioxidants & Redox Signaling : 26 : [DOI : 10.1089/ars.2016.6750](https://doi.org/10.1089/ars.2016.6750)

Lefort, A Thuleau, Y Kieffer, P Sirven, I Bieche, E Marangoni, A Vincent-Salomon & F Mechta-Grigoriou (2017 Mar 2)

CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients

Oncogene : 1211-1222 : [DOI : 10.1038](https://doi.org/10.1038)

Année de publication : 2016

Tina Grusso, Virginie Mieulet, Melissa Cardon, Brigitte Bourachot, Yann Kieffer, Flavien Devun, Thierry Dubois, Marie Dutreix, Anne Vincent-Salomon, Kyle Malcolm Miller, Fatima Mechta-Grigoriou (2016 Mar 24)

Chronic oxidative stress promotes H2AX protein degradation and enhances chemosensitivity in breast cancer patients.

EMBO molecular medicine : 527-49 : [DOI : 10.15252/emmm.201505891](https://doi.org/10.15252/emmm.201505891)

Luciana Batista, Brigitte Bourachot, Bogdan Mateescu, Fabien Rey, Fatima Mechta-Grigoriou (2016 Jan 5)

Regulation of miR-200c/141 expression by intergenic DNA-looping and transcriptional read-through.

Nature communications : 8959 : [DOI : 10.1038/ncomms9959](https://doi.org/10.1038/ncomms9959)

Année de publication : 2015

Tina Gruosso, Camille Garnier, Sophie Abelanet, Yann Kieffer, Vincent Lemesre, Dorine Bellanger, Ivan Bieche, Elisabetta Marangoni, Xavier Sastre-Garau, Virginie Mieulet, Fatima Mechta-Grigoriou (2015 Oct 13)

MAP3K8/TPL-2/COT is a potential predictive marker for MEK inhibitor treatment in high-grade serous ovarian carcinomas.

Nature communications : 8583 : [DOI : 10.1038/ncomms9583](https://doi.org/10.1038/ncomms9583)